TickerFacts.

Company research / ORGO

Organogenesis Holdings Inc. (ORGO)

Build a valuation ↗↓ Download CSV

CIK 0001661181 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Organogenesis Holdings Inc. reported revenue of $564.17M. Revenue grew 17.0% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $457.45M.

Key ratios (year ended 2025-12-31)

7.9%
Operating margin
6.6%
Net margin
12.3%
Return on year-end equity
17.0%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-08-06

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312022-03-312021-12-312020-12-312019-12-312018-12-312017-12-31
Revenue$457.45M$564.17M$482.04M$433.14M$450.89Mn/a$467.36M$338.30M$260.98M$193.45M$198.51M
Cost of Revenuen/an/a$115.74M$106.48M$105.02Mn/a$114.20M$87.32M$75.95M$68.81M$61.22M
Gross Profitn/an/a$366.30M$326.66M$345.87Mn/a$353.16M$250.98M$185.03M$124.64M$137.29M
R&D Expense$56.97M$44.54M$50.27M$44.38M$39.76Mn/a$30.74M$20.09M$14.80M$10.74M$9.06M
Operating Income-$35.87M$44.69M-$1.28M$12.53M$22.30Mn/a$72.22M$26.70M-$29.85M-$51.56M-$5.49M
Depreciation & Amortization$15.94M$15.27M$13.62M$10.45M$5.84Mn/an/an/an/an/an/a
EBITDA-$19.93M$59.97M$12.34M$22.97M$28.15Mn/an/an/an/an/an/a
Net Income-$84.16M$37.03M$861.0K$4.95M$15.53Mn/a$94.20M$17.23M-$38.71M-$64.83M-$8.39M
EPS (Diluted)n/a$0.15-$0.01$0.04$0.12n/a$0.70$0.15-$0.42-$0.94n/a
Total Assets$406.45M$598.73M$497.89M$460.02M$449.36Mn/a$443.26M$290.22M$220.69M$163.68M$148.72M
Total Liabilities$118.31M$164.81M$112.57M$181.36M$183.69M$194.74M$201.92M$148.41M$165.10M$116.64M$157.28M
Long-Term Debtn/an/an/a$66.56M$71.25Mn/a$74.06M$70.00Mn/an/a$52.14M
Shareholders' Equity$148.27M$300.13M$262.90M$278.66M$265.67M$241.53M$241.34M$141.81M$52.02M$47.04M-$15.32M
Cash & Equivalents$46.10M$93.68M$135.57M$103.84M$102.48Mn/a$113.93M$84.39Mn/an/an/a
Operating Cash Flow$31.97M-$10.31M$14.21M$30.92M$24.86Mn/a$61.98M$5.47M-$33.53M-$60.63M-$3.49M
Capital Expenditures$11.13M$14.15M$10.03M$24.36M$33.90Mn/a$31.22M$17.68M$5.98M$1.86M$2.43M
Free Cash Flow$20.84M-$24.46M$4.18M$6.55M-$9.04Mn/a$30.76M-$12.21M-$39.51M-$62.49M-$5.92M
Share Repurchasesn/an/a$25.48M$0$0n/an/an/an/an/an/a
Shares Outstanding128.67M126.95M125.73M131.32M130.92Mn/a128.68M127.73M104.87M91.26M66.98M
Weighted Average Diluted Sharesn/a130.25M131.67M132.75M132.38Mn/a133.66M111.36M92.84M69.32Mn/a
EPS (Basic)n/a$0.16-$0.01$0.04$0.12n/a$0.73$0.16-$0.42-$0.94n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView